ISSN 2149-2263 | E-ISSN 2149-2271
pdf
Is endocan a biochemical marker for asymptomatic target organ damage in hypertensive patients? [Anatol J Cardiol]
Anatol J Cardiol. 2019; 21(2): 76-82 | DOI: 10.14744/AnatolJCardiol.2018.25564

Is endocan a biochemical marker for asymptomatic target organ damage in hypertensive patients?

Mustafa Tarık Ağaç1, Behlül Kahyaoğlu1, Muhammed Murat Necati Aksoy1, Fatma Behice Cinemre2, Mehmet Bülent Vatan1, Yasemin Gündüz3
1Department of Cardiology, Faculty of Medicine, Sakarya University; Sakarya-Turkey
2Department of Biochemistry, Faculty of Medicine, Sakarya University; Sakarya-Turkey
3Department of Radiology, Faculty of Medicine, Sakarya University; Sakarya-Turkey

Objective: Identification of the asymptomatic target organ damage (AOD) helps to stratify the overall risk of cardiovascular (CV) diseases and guides a treatment decision in hypertensive patients without a symptomatic CV or renal disease. The endothelial-cell-specific molecule 1 (endocan) is regarded as a novel marker of endothelial dysfunction. Its release is increased in hypertensive patients, especially those with symptomatic CV and renal disease. In the present study, we aimed to evaluate the endocan levels in asymptomatic hypertensive patients with or without AOD.
Methods: The study included 132 asymptomatic hypertensive patients, and 101 of who had at least one AOD.
Results: Serum endocan levels did not differ between patients with and without AOD (3.81±0.78 vs. 3.83±0.63 ng/mL, p=0.88). An analysis according to the presence of any specific AOD did not show any difference between groups. No significant correlation was found between serum endocan levels and any of the continuous variables related to AOD, such as the pulse pressure, carotid intimae-media thickness, cardio-ankle vascular index, ankle-brachial index, left ventricular mass index, Sokolow–Lyon index, Cornell voltage-duration product, and estimated glomerular filtration rate.
Conclusion: Endocan may not serve as a useful biomarker at asymptomatic vascular stages of hypertension, despite its role in indicating disease severity and inflammatory activation in advanced symptomatic CV and renal disease.

Keywords: endocan, asymptomatic target organ damage, hypertension

Mustafa Tarık Ağaç, Behlül Kahyaoğlu, Muhammed Murat Necati Aksoy, Fatma Behice Cinemre, Mehmet Bülent Vatan, Yasemin Gündüz. Is endocan a biochemical marker for asymptomatic target organ damage in hypertensive patients?. Anatol J Cardiol. 2019; 21(2): 76-82

Corresponding Author: Mustafa Tarık Ağaç, Türkiye
Manuscript Language: English


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 The Anatolian Journal of Cardiology



Kare Publishing is a subsidiary of Kare Media.